The current drug development paradigm, which relies on labor-intensive experimental iterations

The gap

Evidence profile

Sourced from the future-work section and stated research gap and future work of the source papers, classified as general, spanning 3 journals. Those papers have been cited 18 times in total.

Supporting evidence — 3 representative gaps

• Design and Application of Stimuli-Responsive Hydrogels for 4D Printing: A Review of Adaptive Materials in Engineering (2026) · Gels · cited 18× · doi

  developing multifunctional hydrogels that combine drug delivery with diagnostic capabilities, enabling theragnostic applications - incorporating artificial intelligence (AI) and machine learning (ML) into hydrogel design could significantly improve their performance and broaden their applicability - establishing predictive models that link molecular design, printing parameters, and post-printing mechanical behavior

  generalfuture-work section
  Keywords: developing multifunctional hydrogels combine drug delivery diagnostic capabilities
• AI-driven drug design: a comprehensive review (2026) · Journal of Computer-Aided Molecular Design · doi

  The gap in the current drug development paradigm, which relies on labor-intensive experimental iterations. The need for a comprehensive review of AI-driven drug design, highlighting its potential in reducing development timelines and costs. The lack of analysis on leading institutions, authors, and journals in the field of AI-driven drug design.

  generalstated research gapevidence 5/5
  Keywords: gap current drug development paradigm relies labor-intensive experimental
• APPLICATION OF ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY AND PHARMACEUTICAL FORMULATION DEVELOPMENT (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi

  Future advancements in artificial intelligence in the pharmaceutical sciences will be expected to concentrate on system-level transformation as opposed to discrete applications. 6.1 AI-POWERED WHOLE-SYSTEM DRUG DEVELOPMENT PROCESS Future platforms might integrate formulation design, manufacturing, lead optimization, and target identification into a continuous AI-assisted workflow. Early discovery data may directly feed formulation and scale-up plans if predictive models communicated across stages rather than operating as separate modules.[41] 6.2 DIGITAL TWIN TECHNOLOGY IN PHARMACEUTICAL MANUFACTURING Digital twin systems, which are virtual duplicates of manufacturing processes that mimic powder flow, compression behaviour, dissolving performance, and stability under various environmental circumstances, may be the next breakthrough in AI for formulation development. By combining artificial intelligence (AI) with sophisticated mathematical modelling tools, manufacturers might anticipate performance variations prior to physical production, increasing productivity and reducing batch failures.[42] 6.3 SELF OPTIMIZING CONTINUOUS MANUFACTURING Artificial intelligence (AI)-driven feedback loops with real-time monitoring and parameter adjustment capabilities may be incorporated into future pharmaceutical production systems. These systems might automatically adjust for changes in material flow, pressure, or www.wjpr.net │ Vol 15, Issue 7, 2026. │ ISO 9001: 2015 Certified Journal │ 440 Arasu et al. World Journal of Pharmaceutical Research temperature to keep product quality within predetermined bounds. The trend toward continuous manufacturing methods in the modern pharmaceutical industry is consistent with this strategy. 6.4 REASONABLE AND RELIABLE AI FRAMEWORK Explainable AI (XAI) models will probably be given priority in future research as AI systems grow more complicated. Clinical adoption and regulatory approval will depend on transparent algorithms that offer interpretable decision routes. Another important area of development will be the creation of standardized validation frameworks for adaptive AI systems.[45] Table 1: Comparison of AI Applications in Drug Discovery and Pharmaceutical Formulation Development.

  generalfuture workevidence 5/5
  Keywords: pharmaceutical manufacturing systems future development formulation artificial intelligence continuous system applications drug discovery models digital

Questions about this gap